Department of Medicine, Divisions of Oncology and Hematology, Stanford University School of Medicine, Stanford, California 94305, USA.
J Biol Chem. 2011 Apr 1;286(13):11035-46. doi: 10.1074/jbc.M110.208470. Epub 2011 Jan 17.
Nucleostemin (NS) is a nucleolar-nucleoplasmic shuttle protein that regulates cell proliferation, binds p53 and Mdm2, and is highly expressed in tumor cells. We have identified NS as a target of oxidative regulation in transformed hematopoietic cells. NS oligomerization occurs in HL-60 leukemic cells and Raji B lymphoblasts that express high levels of c-Myc and have high intrinsic levels of reactive oxygen species (ROS); reducing agents dissociate NS into monomers and dimers. Exposure of U2OS osteosarcoma cells with low levels of intrinsic ROS to hydrogen peroxide (H(2)O(2)) induces thiol-reversible disulfide bond-mediated oligomerization of NS. Increased exposure to H(2)O(2) impairs NS degradation, immobilizes the protein within the nucleolus, and results in detergent-insoluble NS. The regulation of NS by ROS was validated in a murine lymphoma tumor model in which c-Myc is overexpressed and in CD34+ cells from patients with chronic myelogenous leukemia in blast crisis. In both instances, increased ROS levels were associated with markedly increased expression of NS protein and thiol-reversible oligomerization. Site-directed mutagenesis of critical cysteine-containing regions of nucleostemin altered both its intracellular localization and its stability. MG132, a potent proteasome inhibitor and activator of ROS, markedly decreased degradation and increased nucleolar retention of NS mutants, whereas N-acetyl-L-cysteine largely prevented the effects of MG132. These results indicate that NS is a highly redox-sensitive protein. Increased intracellular ROS levels, such as those that result from oncogenic transformation in hematopoietic malignancies, regulate the ability of NS to oligomerize, prevent its degradation, and may alter its ability to regulate cell proliferation.
核干细胞蛋白 (NS) 是一种核仁-核质穿梭蛋白,可调节细胞增殖,与 p53 和 Mdm2 结合,在肿瘤细胞中高度表达。我们已经确定 NS 是转化造血细胞中氧化调节的靶标。HL-60 白血病细胞和 Raji B 淋巴母细胞中 NS 发生寡聚化,这些细胞表达高水平的 c-Myc,并且具有高内在活性氧 (ROS) 水平;还原剂将 NS 解离为单体和二聚体。用低水平内在 ROS 的 U2OS 骨肉瘤细胞暴露于过氧化氢 (H₂O₂) 可诱导 NS 的巯基可逆二硫键介导的寡聚化。增加对 H₂O₂的暴露会损害 NS 的降解,使蛋白质固定在核仁内,并导致去污剂不溶性 NS。ROS 对 NS 的调节在过表达 c-Myc 的小鼠淋巴瘤肿瘤模型和慢性髓性白血病急变期的 CD34+细胞中得到了验证。在这两种情况下,ROS 水平的增加与 NS 蛋白表达和巯基可逆寡聚化的显著增加相关。核干细胞蛋白关键半胱氨酸残基的定点突变改变了其细胞内定位及其稳定性。MG132 是一种有效的蛋白酶体抑制剂和 ROS 激活剂,可显著减少 NS 突变体的降解并增加核仁保留,而 N-乙酰-L-半胱氨酸则在很大程度上阻止了 MG132 的作用。这些结果表明 NS 是一种高度的氧化还原敏感蛋白。造血恶性肿瘤中致癌转化导致的细胞内 ROS 水平增加可调节 NS 寡聚化的能力,防止其降解,并可能改变其调节细胞增殖的能力。